For the sixth year consecutive year, IMARC is presenting its Top 10 Warning Letter findings for your review.
Topics: BIMO Metrics, Top 10, FDA, Warning Letters
The FDA Bioresearch Monitoring Program (BIMO) was created to: “Protect the rights, safety, and welfare of human research subjects involved in FDA-regulated clinical trials; Verify the accuracy and reliability of clinical trial data submitted to FDA in support of research or marketing applications; and To assess compliance with statutory requirements and FDA's regulations governing the conduct of clinical trials.” But, how exactly does FDA safeguard human subjects, ensure data integrity, and verify compliance with applicable standards?
Topics: BIMO Metrics, IMARC Research, FDA, Warning Letters
